New York, New York, USA

Ro

Privately held American direct-to-patient telehealth company. It describes itself as offering online clinician visits, labs and pharmacy services on one platform, founded in 2017. It is not the maker of any approved GLP-1 drug. Its press releases describe working with Eli Lilly and Novo Nordisk so that its patients can be prescribed their branded, FDA-approved obesity medicines. Ro is privately held, and none of the sources cited here gives a revenue figure. Facts below come from Ro's own press releases, cited as archived copies because ro.co blocks automated access.

Lilly collaboration (December 2024)

On 11 December 2024 Ro announced it was working with Eli Lilly to streamline access to Zepbound (tirzepatide) single-dose vials for Ro patients with obesity, through an integration with Lilly's LillyDirect self-pay pharmacy channel and with an on-label prescription from a Ro-affiliated provider.[src]

Novo Nordisk collaboration (January 2026)

On 5 January 2026 Ro announced it was working with Novo Nordisk on the nationwide launch of the Wegovy pill. Ro's release says it first integrated directly with Novo Nordisk in April 2025.[src]

Foundayo (April 2026)

On 9 April 2026 Ro announced that eligible patients could access Foundayo (orforglipron), described in its release as Eli Lilly's once-daily oral treatment for adults with obesity or overweight with weight-related medical problems.[src]

Funding disclosed by the company

In a press release dated 23 March 2021 (New York, NY dateline), Ro announced a $500 million Series D funding round and said its total funding since founding in 2017 had reached $876 million.[src]